Telavant, a Roivant company, is developing innovative therapies to help patients living with inflammatory and fibrotic diseases. Telavant’s first investigational product, RVT-3101, is a fully human monoclonal antibody targeting TL1A. In nonclinical studies and in clinical trials conducted to date, RVT-3101 has been observed to neutralize TL1A signaling. TL1A has been shown to modulate the location and severity of inflammation and fibrosis by stimulating TH1 and TH17 pathways, in addition to activating fibroblasts. The company is developing RVT-3101 as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis and Crohn’s disease, including for patients with a prospectively defined biomarker who may benefit from a precision approach utilizing RVT-3101.